Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

The financial outlook for DexCom appears positive due to several key momentum drivers, including anticipated Medicare expansion and additional coverage wins that are expected to enhance the number of covered lives significantly. The company's recent innovations, such as the G7 15-day continuous glucose monitoring system and an improved adhesive patch, are likely to stimulate demand and drive revenue growth, alongside an expected robust increase in earnings per share. Furthermore, operational efficiency improvements and sales force productivity are projected to support DexCom's objectives of achieving mid-teens revenue growth and over 20% EPS growth through 2028.

Bears say

DexCom reported sensor revenue of $1.18 billion for the year, indicating a year-over-year growth of 20%, but the hardware revenue of $34 million saw a significant decline of 31% year-over-year. The company's fiscal year 2026 revenue guidance of $5.16 billion to $5.25 billion is slightly below consensus expectations and reflects anticipated deceleration in 4Q US sales, attributed to shifting seasonality and a growing reliance on pharmacy distribution. Furthermore, with the company's recent history of decelerating growth and execution challenges, there are concerns that DexCom shares may continue to trade at a discount compared to competitors, suggesting a prolonged negative outlook.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.